[go: up one dir, main page]

WO2013154771A1 - Oxyde nitrique synthase résistant à l'oxydoréduction - Google Patents

Oxyde nitrique synthase résistant à l'oxydoréduction Download PDF

Info

Publication number
WO2013154771A1
WO2013154771A1 PCT/US2013/032361 US2013032361W WO2013154771A1 WO 2013154771 A1 WO2013154771 A1 WO 2013154771A1 US 2013032361 W US2013032361 W US 2013032361W WO 2013154771 A1 WO2013154771 A1 WO 2013154771A1
Authority
WO
WIPO (PCT)
Prior art keywords
enos
redox
cell
resistant
nitric oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/032361
Other languages
English (en)
Inventor
Stephen Black
Ruslan Rafikov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Augusta University
Original Assignee
Georgia Regents University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgia Regents University filed Critical Georgia Regents University
Publication of WO2013154771A1 publication Critical patent/WO2013154771A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C12N9/0075—Nitric-oxide synthase (1.14.13.39)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)

Definitions

  • the invention is generally directed to recombinant proteins and there use in treating cardiovascular disease.
  • Cardiovascular disease is associated with a number of different disorders including hypercholesterolaemia, hypertension and diabetes.
  • the underlying pathology for most cardiovascular diseases is atherosclerosis, which is in turn associated with endothelial dysfunctional.
  • Nitric oxide (NO) plays an important role in the protection against the onset and progression of cardiovascular disease by regulating blood pressure and vascular tone, inhibiting platelet aggregation and leukocyte adhesion, and preventing smooth muscle cell proliferation.
  • Reduced bioavailability of NO is thought to be one of the central factors common to cardiovascular disease, although it is unclear whether this is a cause of, or result of, endothelial dysfunction. Disturbances in NO bioavailability leads to a loss of the cardioprotective actions and in some cases may even increase disease progression.
  • Nitric oxide is synthesized from a family of enzymes known as nitric oxide synthases (NOS).
  • NOS nitric oxide synthases
  • One NOS is endothelial nitric oxide synthase (eNOS).
  • eNOS is found primarily in endothelial cells in the vasculature and is associated with several vascular diseases, such as atherosclerosis, hypertension and erectile dysfunction.
  • Redox-resistant nitric oxide synthases are provided.
  • the redox- resistant nitric oxide synthases have been engineered to replace the oxidant sensitive ZnS 4 cluster with a redox stable tetra-arginine cluster.
  • the resulting enzyme is fully functional, is resistant to dimer disruption by oxidative stress, and retains the ability to produce NO under conditions in which the wildtype enzyme is severely inhibited.
  • An exemplary redox- resistant nitric oxide synthase contains a C94R and C99R substitution relative to SEQ ID NO: 1 also represented as SEQ ID NO:2.
  • the redox-resistant nitric oxide synthase forms a dimer, for example a homodimer.
  • the dimer forms a complex with P0 4 "3 .
  • Cells that contain the redox resistant nitric oxide synthase are also described.
  • Exemplary cells are mammalian cells that have been genetically engineered to express one or more redox-resistant nitric oxide synthases.
  • the mammalian cell is preferably a human endothelial progenitor cell.
  • Methods of treating a disease associated with the NO signaling transduction pathway are also provided.
  • Representative diseases that can be treated include, but are not limited to diseases related to eNOS dysfunction.
  • Preferred diseases to be treated include cardiovascular disease.
  • Cardiovascular disease includes atherosclerosis and hypertension.
  • Preferred methods of treatment include administering to a subject cells that have been genetically engineered to express a redox-resistant eNOS.
  • the cells are preferably progenitor cells including autologous endothelial progenitor cells.
  • Other methods of treatment include delivering redox-resistant eNOS protein or nucleic acids encoding the redox-resistant eNOS to the subject.
  • Methods of increasing nitric oxide (NO) production in a cell are also provided.
  • the increase in NO production is relative to cells that have not been treated with the disclosed compositions.
  • An increase in NO production in a cell can be accomplished by administering an effective amount of a composition comprising a redox-resistant eNOS or nucleic acids encoding the redox-resistant eNOS.
  • Figure 1 shows the structure of Zn-tetrathiolate cluster.
  • the cluster is composed of two cysteine residues (C94 and C99, human nomenclature) from each subunit of eNOS. Oxidation of cysteine residues within the Zn4 cluster requires less energy due to formation of three electron S-S bond in the tetrahedral coordination.
  • Figure 2 shows an ion cluster inversion.
  • wildtype eNOS contains a Zn cluster with four negatively charged sulfur atoms surrounding the Zn 2+ cation in a tetrahedral configuration.
  • C94R/C99R redox-resistant eNOS the introduction of four arginine residue are proposed to stabilize the dimeric interface of eNOS via electrostatic interactions with a P0 4 3" anion.
  • the lower panel shows both the crystal structure of the Zn cluster (PDB ID 3NOS) in wildtype eNOS and computer simulated structure.
  • Figures 3A and 3B are line graphs of absorbance (at ⁇ 260 ⁇ ) versus filtration fraction.
  • Figure 3A shows a gel filtration profile (absorbance at ⁇ 260 ⁇ ) of WT (solid)-, C94R/C99R (dash)- and C94A/C99A(dot)-eNOS.
  • WT- and C94R/C99R-eNOS form dimeric proteins in contrast to the C94A/C99A redox-resistant eNOS.
  • Figure 3B shows a gel filtration analysis of WT (solid)- and C94R/C99R (dash)-eNOS treated with 0.5mM H202. H2O2 treatment disrupts the dimeric structure of WT eNOS, but the
  • C94R/C99R redox-resistant eNOS is resistant to monomerization.
  • Figures 4A and 4B show western blots of WT and redox-resistant eNOS exposed to increasing levels of H2O2 as well as bar graphs showing dimer/monomer ration (fold untreated) versus increasing H2O2
  • FIG. 4A shows a dose dependant decrease in dimer content for WT eNOS while Figure 4B shows that the C94R/C99R redox-resistant eNOS was resistant to dimer disruption even at 400 ⁇ H 2 02.
  • Figure 4C is a bar graph of NO production
  • an effective amount or “therapeutically effective amount” means a dosage sufficient to treat, inhibit, or alleviate one or more symptoms of a disease state being treated or to otherwise provide a desired pharmacologic and/or physiologic effect.
  • the precise dosage will vary according to a variety of factors such as subject-dependent variables (e.g., age, immune system health, etc.), the disease, and the treatment being effected.
  • an effective amount of the disclosed compositions is an amount that increases NO production in a subject in amount effective to reduce or alleviate one or more symptoms of cardiovascular disease.
  • allogeneic is meant to refer to any materia] derived from a different mamma] of the same species.
  • eNOS refers to endothelial nitric oxide synthase, preferably human endothelial nitric oxide synthase.
  • NO refers to nitric oxide
  • nucleic acid molecule encoding refers to the order or sequence of nucleotides along a strand of nucleotides. The order of these nucleotides determines the order of amino acids along the polypeptide (protein) chain. The nucleotide sequence thus codes for the amino acid sequence.
  • protein includes proteins, protein variants, peptides and peptide variants.
  • a redox-resistant eNOS refers to an eNOS enzyme that has been modifed to be more resistant to oxidative stress relative to unmodified eNOS or wildtype eNOS.
  • redox-resistant eNOS is shown in Figures 4A-C and demonstrates increased dimer formation relative to wildtype eNOS in the presence of H2O2.
  • the term includes truncated proteins relative to SEQ ID NO: l that retain eNOS enzymatic activity and redox-resistance.
  • stem cell refers both to the earliest renewable cell population responsible for generating cell mass in a tissue or body and the very early progenitor cells, which are somewhat more differentiated, yet are not committed and can readily revert to become a part of the earliest renewable cell population.
  • Methods for the ex- vivo culturing of stem cells are well known in the art of cell culturing ("Culture of Animal Cells— A Manual of Basic Technique” by Freshney, Wiley -Liss, N.Y. (1994), Third Edition).
  • subject refers to any individual who is the target of administration.
  • the subject can be a vertebrate, for example, a mammal.
  • the subject can be a human.
  • the term does not denote a particular age or sex.
  • treatment and “treating” is meant the medical management of a subject with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder.
  • This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder.
  • this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.
  • palliative treatment that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder
  • preventative treatment that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder
  • supportive treatment that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.
  • the effects of treatment can be measured or assessed as described herein and as known in the art as is suitable for the disease, pathological condition, or disorder involved. Such measurements and assessments can be made in qualitative and/or quantitative terms.
  • PTD Protein Transduction Domain
  • a PTD attached to another molecule facilitates the molecule traversing membranes, for example going from extracellular space to intracellular space, or cytosol to within an organelle.
  • Exemplary PTDs include, but are not limited to, HIV TAT,
  • YGRKKRRQRRR (SEQ ID NO: 3), or RKKRRQRRR (SEQ ID NO: 4); 1 1 Arginine residues, or positively charged polypeptides or polynucleotides having 8-15 residues, preferably 9-11 residues.
  • redox-resistant nitric oxide synthases can be produced by replacing the oxidant sensitive ZnS 4 cluster with a redox stable cluster.
  • the redox stable cluster is preferably a tetra-arginine cluster.
  • the redox-resistant nitric oxide synthases can be used to treat one or more symptoms of diseases related to the NO signal transduction pathway.
  • the disclosed redox-resistant nitric oxide synthases produce NO under conditions that typically result in the down-regulation of NO production, i.e., oxidative stress.
  • the redox-resistant nitric oxide synthases can function in the disease state to treat one or more symptoms of cardiovascular disease.
  • Endothelial nitric oxide synthase eNOS
  • Nitric oxide synthases are a family of enzymes that catalyze the production of nitric oxide (NO) from L-arginine. NO is an important cellular signaling molecule involved in many physiological and pathological processes affecting nearly every organ system in the body. Endothelial nitric oxide synthase (eNOS) is a key producer of NO found in the vascular system. eNOS is expressed in vascular endothelium, airway epithelium, and certain other cell types where it generates the key signaling molecule NO. Diminished NO availability contributes to systemic and pulmonary hypertension, atherosclerosis, and airway dysfunction.
  • eNOS Endothelial nitric oxide synthase
  • eNOS dependant vasodilation is an important mechanism regulating vascular tone, the oxidative stress induced disruption of normal eNOS function can induce pathological changes in blood vessels.
  • Wild type eNOS contains cysteine residues at positions 94 and 99. These cysteines play a role in the formation of eNOS dimers and zinc tetrathiolate.
  • redox-resistant eNOS from other mammalian species. These redox-resistant eNOS proteins can be produced by replacing the oxidant sensitive ZnS 4 cluster with a redox stable tetra- arginine cluster.
  • eNOS enzyme proteins-protein interactions and different signal transduction events play a role in modifying eNOS activity.
  • the active form of eNOS enzyme exists as two identical subunits that form a head to tail homodimer.
  • cysteines 94 and 99 of eNOS form a zinc tetra-coordinated (ZnS 4 ) cluster between each subunit.
  • Zinc bound to the tetrathiolate cluster has also been shown to stabilize the dimer interface on the N-terminal region of eNOS (Raman et al. Cell 95:939- 950, 1998; Hemmens et al. Journal of Biological Chemistry 275 35786- 35791, 2000).
  • ZnS 4 cluster is highly sensitive to oxidants such as ONOO , NO, and 3 ⁇ 4(3 ⁇ 4 (Zou et al. J. of Clinical
  • Metallo-enzymes can coordinate zinc ions (Zn) through cysteine or histidine residues.
  • the Zn ion can coordinate four ligands in a tetrahedral structure.
  • the ZnS 4 cluster in endothelial nitric oxide synthase (eNOS) can be important for eNOS activity.
  • Endothelial NOS like all NOS isoforms, is a homodimeric enzyme with the ZnS 4 cluster at the dimer interface.
  • the cluster is formed by four sulfur atoms from two cysteine residues C94 and C99 from each monomer (Fig. 1). It is well established that the dimeric configuration is required for NO formation (Raman, et al.
  • the distance between sulfur atoms in the ZnS cluster is equal to the distance between sulfur atoms in (S-S) disulfide bond. Therefore, the formation of an intermediate with a two-center three-electron bond between two sulfur atoms is very favorable (Fig.1) (Lu, et al. Biochim BiophysActa 2001, 1525, 89-96). Further oxidation of the three-electron (S-S) intermediate requires significantly less energy, therefore, oxidation of cysteine residues in ZnS4 cluster can occur even under mild oxidative stress.
  • redox- resistant nitric oxide synthases can be produced by replacing the oxidant sensitive ZnS 4 cluster with a redox stable cluster.
  • the redox stable cluster is preferably a tetra-arginine cluster.
  • One embodiment provides a redox- resistant eNOS containing the double mutant C94R/C99R relative to wildtype (SEQ ID NO: 1).
  • the wildtype ZnS 4 cluster can be modified by replacing one or both cysteine residues with arginine or other amino acid residues that reduces the sensitivity of the protein to oxidative stress.
  • SEQ ID NO:2 shows the amino acid sequence of eNOS containing the
  • the redox-resistant eNOS can include the full length eNOS protein or eNOS peptides that are able to form homodimers and produce NO.
  • the redox-resistant eNOS can contain fewer amino acids than full length eNOS.
  • the redox-resistant eNOS may be longer than full length eNOS.
  • Active forms of the eNOS protein or redox- resistant eNOS can be used. Active eNOS is any variant of eNOS that is capable of producing NO.
  • Redox-resistant eNOS peptides retain at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% of enzyme activity.
  • the redox-resistant eNOS can have greater than 100% of wild type enzyme activity.
  • Redox-resistant eNOS can form dimers with full length eNOS, an eNOS peptide, another redox-resistant eNOS or a redox-resistant eNOS peptide.
  • the disclosed peptides can be in isolated form.
  • isolated means a peptide that is in a form that is relatively free from material such as contaminating polypeptides, lipids, nucleic acids and other cellular material that normally is associated with the peptide in a cell or that is associated with the peptide in a library or in a crude preparation.
  • the disclosed peptides can have any suitable length sufficient to produce nitric oxide.
  • Redox-resistant eNOS from other species can also be used.
  • One of skill in the art would understand what mutations in an eNOS from another species would correspond to the mutations described for human eNOS.
  • Redox-resistant eNOS proteins can be monomeric or dimeric, and only dimers are enzymatically active.
  • the dimer is composed of two redox-resistant eNOS protein monomers containing the same mutations. Dimers containing the same monomers are homodimers.
  • the dimer is composed of two redox-resistant eNOS proteins wherein one protein monomer contains the C94R/C99R mutations and the other protein monomer contains one or more different mutations. Dimers containing different monomers are heterodimers.
  • the redox-resistant eNOS dimers retain at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% of wild type activity enzymatic activity.
  • Heterodimers between the redox-resistant eNOS monomer and wildtype eNOS monomer can also form.
  • the dimer can form a complex with a Zn 2+ ion.
  • the dimer can form a complex with a phosphate ion (P0 4 ⁇ 3 ).
  • a "methylated derivative" of a protein refers to a form of the protein that is methylated. Unless the context indicates otherwise, reference to a methylated derivative of a protein does not include any modification to the base protein other than methylation. Methylated derivatives can also have other modifications, but such modifications generally will be noted. For example, conservative variants of an amino acid sequence would include conservative amino acid substitutions of the based amino acid sequence.
  • a “methylated derivative" of a specific amino acid sequence "and conservative variants thereof would include methylated forms of the specific amino acid sequence and methylated forms of the conservative variants of the specific amino acid sequence, but not any other modifications of derivations.
  • reference to a methylated derivative of an amino acid segment that includes amino acid substitutions would include methylated forms of the amino acid sequence of the amino acid segment and methylated forms of the amino acid sequence of the amino acid segment include amino acid substitutions.
  • Protein variants and derivatives are well understood by those of skill in the art and can involve amino acid sequence modifications.
  • amino acid sequence modifications typically fall into one or more of three classes: substitutional, insertional or deletional variants.
  • Insertions include amino and/or carboxyl terminal fusions as well as intrasequence insertions of single or multiple amino acid residues. Insertions ordinarily will be smaller insertions than those of amino or carboxyl terminal fusions, for example, on the order of one to four residues.
  • Immunogenic fusion protein derivatives such as those described in the examples, are made by fusing a polypeptide sufficiently large to confer immunogenicity to the target sequence by cross- linking in vitro or by recombinant cell culture transformed with DNA encoding the fusion. Deletions are characterized by the removal of one or more amino acid residues from the protein sequence. Typically, no more than about from 2 to 6 residues are deleted at any one site within the protein molecule. These variants ordinarily are prepared by site specific
  • mutagenesis of nucleotides in the DNA encoding the protein, thereby producing DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture.
  • Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example Ml 3 primer mutagenesis and PCR mutagenesis.
  • Amino acid substitutions are typically of single residues, but can occur at a number of different locations at once; insertions usually will be on the order of about from 1 to 10 amino acid residues; and deletions will range about from 1 to 30 residues.
  • Deletions or insertions preferably are made in adjacent pairs, i.e. a deletion of 2 residues or insertion of 2 residues. Substitutions, deletions, insertions or any combination thereof can be combined to arrive at a final construct.
  • the mutations must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure.
  • a “conservative variant” is a sequence in which a first amino acid is replaced by another amino acid or amino acid analog having at least one biochemical property similar to that of the first amino acid; similar properties include, for example, similar size, charge, hydrophobicity or hydrogen-bonding capacity.
  • Conservative variants are also referred to herein as “conservative amino acid substitutions,” “conservative amino acid variants,” “conservative substitutions,” and similar phrase.
  • a “conservative derivative” of a reference sequence refers to an amino acid sequence that differs from the reference sequences only in conservative substitutions.
  • a conservative variant can be a sequence in which a first uncharged polar amino acid is conservatively substituted with a second (non-identical) uncharged polar amino acid such as cysteine, serine, threonine, tyrosine, glycine, glutamine or asparagine or an analog thereof.
  • a conservative variant also can be a sequence in which a first basic amino acid is conservatively substituted with a second basic amino acid such as arginine, lysine, histidine, 5 -hydroxy lysine, N-methyllysine or an analog thereof.
  • a conservative variant can be a sequence in which a first hydrophobic amino acid is conservatively substituted with a second hydrophobic amino acid such as alanine, valine, leucine, isoleucine, proline, methionine, phenylalanine or tryptophan or an analog thereof.
  • a conservative variant can be a sequence in which a first acidic amino acid is conservatively substituted with a second acidic amino acid such as aspartic acid or glutamic acid or an analog thereof; a sequence in which an aromatic amino acid such as phenylalanine is conservatively substituted with a second aromatic amino acid or amino acid analog, for example, tyrosine; or a sequence in which a first relatively small amino acid such as alanine is substituted with a second relatively small amino acid or amino acid analog such as glycine or valine or an analog thereof.
  • the replacement of one amino acid residue with another that is biologically and/or chemically similar is known to those skilled in the art as a conservative substitution.
  • a conservative substitution would be replacing one hydrophobic residue for another or one polar residue for another.
  • the substitutions include combinations such as, for example, Gly, Ala; Val, He, Leu; Asp, Glu; Asn, Gin; Ser, Thr; Lys, Arg; and Phe, Tyr.
  • conservatively substituted variations of each explicitly disclosed sequence are included within the mosaic polypeptides provided herein. It is understood that conservative variants of the disclosed amino acid sequences can encompass sequences containing, for example, one, two, three, four or more amino acid substitutions relative to the reference sequence, and that such variants can include naturally and non-naturally occurring amino acid analogs.
  • substitutional variants are those in which at least one residue has been removed and a different residue inserted in its place. Examples of such substitutions, referred to as conservative substitutions, can generally in accordance with the following Table 1.
  • substitutions that are less conservative, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain.
  • the substitutions which in general are expected to produce the greatest changes in the protein properties will be those in which (a) a hydrophilic residue, e.g. seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an amino acid residue, e.g. seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g
  • electropositive side chain e.g., lysyl, arginyl, or histidyl
  • an electronegative residue e.g., glutamyl or aspartyl
  • a residue having a bulky side chain e.g., phenylalanine
  • one not having a side chain e.g., glycine
  • Peptides can have a variety of modifications. Modifications can be used to change or improve the properties of the peptides.
  • the disclosed peptides can be N-methylated, O-methylated, S-methylated, C- methylated, or a combination at one or more amino acids.
  • amino and/or carboxy termini of the disclosed peptides can be modified.
  • Amino terminus modifications include methylation (e.g.,— HCH 3 or— (CH 3 ) 2 ), acetylation (e.g., with acetic acid or a halogenated derivative thereof such as a -chloroacetic acid, a-bromoacetic acid, or a-iodoacetic acid), adding a benzyloxycarbonyl (Cbz) group, or blocking the amino terminus with any blocking group containing a carboxylate functionality defined by RCOO- or sulfonyl functionality defined by R-SO 2 -, where R is selected from the group consisting of alkyl, aryl, heteroaryl, alkyl aryl, and the like, and similar groups.
  • the N-terminus is acetylated with acetic acid or acetic anhydride.
  • Carboxy terminus modifications include replacing the free acid with a carboxamide group or forming a cyclic lactam at the carboxy terminus to introduce structural constraints.
  • C- terminal functional groups of the disclosed peptides include amide, amide lower alkyl, amide di(lower alkyl), lower alkoxy, hydroxy, and carboxy, and the lower ester derivatives thereof, and the pharmaceutically acceptable salts thereof.
  • proline analogues in which the ring size of the proline residue is changed from 5 members to 4, 6, or 7 members can be employed.
  • Cyclic groups can be saturated or unsaturated, and if unsaturated, can be aromatic or non-aromatic. Heterocyclic groups preferably contain one or more nitrogen, oxygen, and/or sulfur heteroatoms. Examples of such groups include the furazanyl, furyl, imidazolidinyl, imidazolyl, imidazolinyl, isothiazolyl, isoxazolyl, morpholinyl (e.g.
  • morpholino oxazolyl, piperazinyl (e.g., 1 -piperazinyl), piperidyl (e.g., 1- piperidyl, piperidino), pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolidinyl (e.g., 1-pyrrolidinyl), pyrrolinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, thiomorpholinyl (e.g., thiomorpholino), and triazolyl.
  • These heterocyclic groups can be substituted or unsubstituted. Where a group is substituted, the substituent can be alkyl, alkoxy, halogen, oxygen, or substituted or unsubstituted phenyl.
  • the proteins can contain modified chemical linkages.
  • a particularly preferred non-peptide linkage is— CH 2 NH— . It is understood that peptide analogs can have more than one atom between the bond atoms, such as ⁇ -alanine, ⁇ -aminobutyric acid, and the like.
  • variants and derivatives of the disclosed amino acids sequences, amino acid segments, peptides, proteins, etc. herein is through defining the variants and derivatives in terms of homology/identity to specific known sequences.
  • variants of these and other amino acids sequences, amino acid segments, peptides, proteins, etc. herein disclosed which have at least, 70% or 75% or 80% or 85% or 90% or 95% homology to the stated sequence.
  • homology can be calculated after aligning the two sequences so that the homology is at its highest level.
  • nucleic acids can be obtained by for example the algorithms disclosed in Zuker, M. Science 244:48-52, 1989, Jaeger et al. Proc. Natl. Acad. Sci. USA 86:7706-7710, 1989, Jaeger et al. Methods Enzymol. 183 :281-306, 1989 which are herein incorporated by reference for at least material related to nucleic acid alignment.
  • Nucleic acids encoding the disclosed redox-resistant eNOS proteins and peptides are readily obtained based on the amino acid sequence of SEQ ID NO: l and other eNOS proteins sequences known in the art using conventional techniques.
  • the nucleic acids typically contain expression control systems.
  • the inserted sequences encoding the redox-resistant eNOS in viral and retroviral systems usually contain promoters, and/or enhancers to help control the expression of the protein.
  • a promoter is generally a sequence or sequences of DNA that function when in a relatively fixed location in regard to the transcription start site.
  • a promoter contains core elements required for basic interaction of RNA polymerase and transcription factors, and may contain upstream elements and response elements.
  • nucleic acids encoding the disclosed peptides operably linked to an expression control sequence are also disclosed.
  • Preferred promoters controlling transcription from vectors in mammalian host cells may be obtained from various sources, for example, the genomes of viruses such as: polyoma, Simian Virus 40 (SV40), adenovirus, retroviruses, hepatitis-B virus and most preferably
  • viruses such as: polyoma, Simian Virus 40 (SV40), adenovirus, retroviruses, hepatitis-B virus and most preferably
  • cytomegalovirus or from heterologous mammalian promoters, e.g. beta actin promoter.
  • the early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment which also contains the SV40 viral origin of replication (Fiers et al, Nature, 273: 1 13 (1978)).
  • the immediate early promoter of the human cytomegalovirus is conveniently obtained as a Hindlll E restriction fragment (Greenway, P. J. et al, Gene 18: 355-360 (1982)).
  • promoters from the host cell or related species can also be used.
  • Enhancer generally refers to a sequence of DNA that functions at no fixed distance from the transcription start site and can be either 5' (Laimins, L. et al, Proc. Natl. Acad. Sci. 78: 993 (1981)) or 3' (Lusky, M. L., et al, Mol. Cell. Bio. 3 : 1 108 (1983)) to the transcription unit. Furthermore, enhancers can be within an intron (Banerji, J. L. et al, Cell 33 : 729 (1983)) as well as within the coding sequence itself (Osborne, T. F., et al, Mol. Cell Bio. 4: 1293 (1984)).
  • Enhancers function to increase transcription from nearby promoters. Enhancers also often contain response elements that mediate the regulation of transcription. Promoters can also contain response elements that mediate the regulation of transcription. Enhancers often determine the regulation of expression of a gene. While many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, a-fetoprotein and insulin), typically one will use an enhancer from a eukaryotic cell virus for general expression.
  • Preferred examples are the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.
  • the promotor and/or enhancer may be specifically activated either by light or specific chemical events which trigger their function.
  • Systems can be regulated by reagents such as tetracycline and dexamethasone.
  • reagents such as tetracycline and dexamethasone.
  • irradiation such as gamma irradiation, or alkylating chemotherapy drugs.
  • the promoter and/or enhancer region can act as a constitutive promoter and/or enhancer to maximize expression of the region of the transcription unit to be transcribed.
  • the promoter and/or enhancer region be active in all eukaryotic cell types, even if it is only expressed in a particular type of cell at a particular time.
  • a preferred promoter of this type is the CMV promoter (650 bases).
  • Other preferred promoters are SV40 promoters, cytomegalovirus (full length promoter), and retroviral vector LTR.
  • Expression vectors used in eukaryotic host cells may also contain sequences necessary for the termination of transcription which may affect mRNA expression. These regions are transcribed as polyadenylated segments in the untranslated portion of the mRNA encoding tissue factor protein. The 3' untranslated regions also include transcription termination sites. It is preferred that the transcription unit also contains a polyadenylation region. One benefit of this region is that it increases the likelihood that the transcribed unit will be processed and transported like mRNA.
  • the identification and use of polyadenylation signals in expression constructs is well established. It is preferred that homologous polyadenylation signals be used in the transgene constructs.
  • the polyadenylation region is derived from the SV40 early polyadenylation signal and contains of about 400 bases. It is also preferred that the transcribed units contain other standard sequences alone or in combination with the above sequences improve expression from, or stability of, the construct.
  • redox resistant NO synthases may be beneficial to administer the redox resistant NO synthases as a pharmaceutical composition.
  • compositions containing the recombinant proteins can include carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like in addition to the molecule of choice.
  • Pharmaceutical compositions can also include one or more active ingredients such as antimicrobial agents, antiinflammatory agents, anesthetics, and the like.
  • Pharmaceutical carriers are known to those skilled in the art. These most typically would be standard carriers for administration of drugs to humans, including solutions such as sterile water, saline, and buffered solutions at physiological pH. The administration can be done according to standard procedures used by those skilled in the art.
  • antibodies that can recognize a redox-resistant eNOS and do not recognize wild type eNOS.
  • the antibody can be polyclonal, monoclonal, bifunctional, humanized, or single chain antibodies.
  • These antibodies can be used to determine the presence of a redox- resistant eNOS in a solution, such as a cell lysate.
  • the antibody can be tagged with a label such as a fluorescent label. Labeled antibodies can be used for in vitro studies.
  • the cell can be autologous or allogeneic.
  • the cells can be primary cells or cell lines.
  • the cells are stem cells or progenitor cells.
  • the progenitor cell can be an endothelial progenitor cell.
  • the redox-resistant eNOS can be introduced into the cell in a variety of ways which are known to those of skill in the art. For example, either the redox-resistant eNOS protein or a nucleic acid encoding the redox-resistant eNOS protein can be used.
  • a cell expressing a nucleic acid encoding redox-resistant eNOS for example SEQ ID NO:2 can be used to provide the redox-resistant eNOS to another cell, tissue, or whole mammal where a higher level of redox-resistant eNOS can be useful to treat or alleviate a disease, disorder or condition associated with eNOS dysfunction. Therefore, disclosed are compositions used to make genetically modified cells expressing redox-resistant eNOS that can b useful to treat or alleviate a disease, disorder or condition involving eNOS dysfunction.
  • Nucleic acids and proteins can be delivered alone or in a
  • composition with or without an adjuvant.
  • nucleic acids can be delivered through a number of direct delivery systems such as, electroporation, lipofection, calcium phosphate
  • Electroporation can be used to get proteins into cells.
  • a protein or nucleic acid can be targeted to a specific cell type using a targeting signal.
  • a carrier such as a protein transduction domain can be used to get a protein into a cell.
  • the eNOs C94R/C99R proteins can include one or more domains for enhancing delivery of the polypeptide across the plasma membrane in into the interior of cells.
  • the eNOs C94R/C99R proteins can be fusion proteins that include a protein transduction domain (PTD), also known as a cell penetrating peptide (CPP).
  • PTDs are known in the art, and include, but are not limited to, small regions of proteins that are able to cross a cell membrane in a receptor-independent mechanism
  • the Antennapedia homeodomain is 68 amino acid residues long and contains four alpha helices.
  • Penetratin is an active domain of this protein which consists of a 16 amino acid sequence derived from the third helix of Antennapedia.
  • TAT Several modifications to TAT, including substitutions of Glutatmine to Alanine, i.e., Q- ⁇ A, have demonstrated an increase in cellular uptake anywhere from 90% (Wender et al, Proc Natl Acad Sci US A., 97(24): 13003-8 (2000)) to up to 33 fold in mammalian cells.
  • PTDs that are cationic or amphipathic.
  • exemplary PTDs include, but are not limited to, poly-Arg - RRRRRRR (SEQ ID NO:5); PTD-5 - RRQRRT SKLMKR (SEQ ID NO:6); Transportan
  • GWTLNSAGYLLGKTNLKALAALAKKIL SEQ ID NO:7
  • KALA - WEAKLAKALAKALAKHLAKALAKALKCEA SEQ ID NO:8
  • RQIKIWFQNRRMKWKK SEQ ID NO:9
  • the fusion protein includes an endosomal escape sequence that improves delivery of the protein to the interior of the cell.
  • Endosomal escape sequences are known in the art, see for example, Barka, et al, Histochem. Cytochem., 48(11): 1453-60 (2000) and Wadia and Stan, Nat. Med., 10(3):310-5 (2004).
  • Preferred methods for treating diseases using the redox resistant NO synthase involve transfecting cells to express the redox resistant NO synthase and administering the transfected cells into a subject in need thereof.
  • the redox resistant NO synthase is administered to a subject in need thereof.
  • the compositions disclosed herein are used to modify cells in culture and then these modified cells are administered to a patient.
  • the cells can be isolated from the subject to be treated (autologous) or from an allogeneic host.
  • the cells can be stem cells, progenitor cells, somatic cells, or embryonic cells.
  • Stem cells are cells capable of producing cell types of more than one lineage.
  • Progenitor cells are cells that can produce different cell types of a single lineage. Cell lineages refer to endoderm, mesoderm, or ectoderm.
  • Exemplary cells that can be used in the disclosed methods include adult stem cells, embryonic stem cells, progenitor cells, adipose-derived stem cells, and somatic cells.
  • Stem cells or progenitor cells can be obtained or isolated from any of a variety of sources, including, but not limited to bone marrow, umbilical cord blood, and/or donor cells from peripheral, circulating blood of any mammal, preferably a human.
  • the stem cells or progenitor cells can be endothelial progenitor cells.
  • An endothelial progenitor cell is a cell that is capable of developing into an endothelial cell or a functional equivalent of an endothelial cell.
  • the stem and/or progenitor cells are derived from a source selected from the group consisting of hematopoietic cells, umbilical cord blood cells, and mobilized peripheral blood cells.
  • Cells can be selected by positive and negative selection techniques. Methods of preparation of stem cells or progenitor cells are well known in the art, commonly selecting cells expressing one or more stem cell markers such as CD34, CD133, etc, or lacking markers of differentiated cells.
  • Endothelial progenitor cells can have specific markers such as CD34, CD31, CD146, Tie2, VE-Cadherin, VEGFR2 or VEGFR3/FLT-4. One or several markers can be used during the selection process. Selection is usually by FACS, or immunomagnetic separation.
  • Embryonic stem cells and methods of their retrieval are well known in the art and are described, for example, in Trounson A O (Reprod Fertil Dev (2001) 13: 523), Roach M L (Methods Mel Biol (2002) 185: 1), and Smith A G (Annu Rev Cell Dev Biol (2001) 17:435).
  • Adult stem cells are stem cells, which are derived from tissues of adults and are also well known in the art. Methods of isolating or enriching for adult stem cells are described in, for example, Miraglia, S. et al. (1997) Blood 90: 5013, Uchida, N. et al. (2000) Proc. Natl. Acad. Sci. USA 97: 14720, Simmons, P.
  • a nucleic acid encoding a redox-resistant eNOS can be introduced into the cell.
  • a redox-resistant eNOS protein is introduced in the cell.
  • the redox-resistant eNOS can aid in nitric oxide production.
  • the redox-resistant eNOS produces nitric oxide under conditions in which wild type eNOS is oxidized and has reduced or no enzymatic activity.
  • eNOS dysfunction Several diseases are associated with eNOS dysfunction.
  • the methods herein preferably treat those diseases in which the eNOS dysfunction is due to oxidative stress.
  • Diseases associated with eNOS dysfunction include, but are not limited to, cardiovascular disease, atherosclerosis, diabetes, erectile dysfunction and vascular disease.
  • Nitric oxide plays an important role in the protection against the onset and progression of cardiovascular disease by regulating blood pressure and vascular tone, inhibiting platelet aggregation and leukocyte adhesion, and preventing smooth muscle cell proliferation.
  • Reduced bioavailability of NO is thought to be one of the central factors common to cardiovascular disease, although it is unclear whether this is a cause of, or result of, endothelial dysfunction. Disturbances in NO bioavailability leads to a loss of the cardioprotective actions and in some case may even increase disease progression.
  • compositions can provide an essential therapeutic benefit.
  • Atherosclerosis occurs when there is an accumulation of fatty materials leading to a thickening of the artery walls.
  • Disease complications include the slowing or stopping of blood flow in the arteries. Because nitric oxide in blood vessels is involved in vasodilation and increasing blood flow, the ability to increase nitric oxide production provides a therapeutic effect for atherosclerosis.
  • nitric oxide is an endothelium-derived relaxing factor, it can have therapeutic effects on hypertension which is a common complication of diabetes. Therefore, redox-resistant eNOS can be used to treat diabetic complications.
  • Erectile dysfunction is a multifactorial disorder that involves the blood flow into sponge-like bodies within the penis.
  • Nitric oxide acts as one of the main vasoactive neurotransmitters. Therefore, reduced nitric oxide plays a role in erectile dysfunction.
  • Redox-resistant eNOS can provide therapeutic effects on penile erection by increasing nitric oxide production.
  • Vascular disease includes those diseases affecting the circulatory pathway, such as the blood vessels.
  • Vascular disease can be characterized as reduced endothelium-mediated vasodilation.
  • Nitric oxide is a key element in endothelial cells that aids in vasodilation. Therefore, in vascular diseases that have reduced vasodilation, administering a redox-resistant eNOS could have beneficial effects.
  • One embodiment provides a method for increasing NO production in a subject by administering the redox-resistant NO synthase, nucleic acids encoding the redox-resistant synthase, cells expressing the redox-resistant NO synthase or a combination thereof.
  • the increase of NO production is relative to the amount of NO production in the subject in the absence of treatment.
  • Methods of increasing NO production in a cell under oxidative stress include administering an effective amount of an oxidant insensitive eNOS.
  • a preferred oxidant insensitve NO synthase is the wild type eNOS containing the C94R and C99R mutations.
  • redox- resistant eNOS dimers can be administered.
  • Methods of inhibiting eNOS dimer disruption in a cell under oxidative stress include administering an effective amount of an oxidant insensitive eNOS.
  • eNOS dimers are necessary for NO production and therefore reducing or inhibiting the disruption of the dimer can be beneficial. Because oxidation can lead to eNOS dimer disruption, the presence of an oxidant insensitive eNOS maintains NO production under oxidative conditions.
  • the disclosed methods can include administering additional therapeutic agents.
  • the disclosed compositions can be administered in combination with any known agents for treating diseases such as, but not limited to, vascular disease, atherosclerosis, diabetes and erectile dysfunction. They can also be administered with known compositions that increase nitric oxide production.
  • the additional therapeutic agents can be, but are not limited to, vasodialating ⁇ -blockers that produce NO release. Examples include nebivolol, labertolol, carvedilol, and bucindolol. Sulfhydryl ACE inhibition, for example zofenopril, can also be used.
  • Statins, high blood pressure medications, anti-platelet medications, blood thinners, and pain medications can all be administered in combination with the disclosed compositions.
  • the therapeutic treatment can be coadministered with another therapeutic agent.
  • Co-administration involves the administration of two or more agents to a subject so that both agents and/or their metabolites are present in the subject at the same time.
  • Co- administration includes simultaneous administration in separate
  • compositions administration at different times in separate compositions, or administration in a composition in which both agents are present.
  • Example 1 Protein engineering to develop a redox resistant endothelial NO synthase
  • C94R/C99R redox-resistant protein a histidine tagged protein was expressed and purified using a bacterial expression system and Ni-NTA affinity chromatography. The protein was further purified by sequential gel-filtration through SephadexTM G-200 and G-25 in the presence of phosphate buffer to enhance the formation of the tetra-arginine cluster.
  • plasmids encoding WT- and the C94R/C99R redox-resistant eNOS were transiently transfected into COS-7 cells using the Effectene transfection reagent (Qiagen). Twenty-four hours after transfection cells were harvested and lysed at 4°C and subjected to low temperature SDS-PAGE and Western blot analysis as previously described (Fonseca, et al. DNA Cell Biol 2010, 29, 149-60).
  • oxidative stress induced disruption of normal eNOS function can induce pathological changes in blood vessels that can lead to a number of generation in WT, but not the C94R/C99R redox-resistant eNOS (Fig. 3 C).
  • the level of NO production was higher in the C94R/C99R redox-resistant compared with WT eNOS (Fig. 3) although the levels of superoxide production measured by EPR (Magnettech) were not different (data not shown).
  • This increase in eNOS activity could be due to the fact that C94R/C99R redox-resistant eNOS is not susceptible to the NO-mediated dimer disruption previously shown in diseases including atherosclerosis, diabetes mellitus and hypertension (Knowles, Jet al.
  • Molecular dynamic (MD) experiments were initially undertaken using the available crystal stucture of human eNOS (PDB ID 3NOS) to determine if mutation of the two tetrathiolate cluster generating cysteine residues to arginines (C94R/C99R) would grossly alter the eNOS structure. Also a phosphate ion (P0 4 3" ) was introduced as a replacement for the Zn 2+ ion. The resulting redox-resistant protein was simulated in a water filled cube for 100ns using the MD simulation module in Yasara. The Amber94 force field was also applied.
  • Figures 4A and 4B demonstrated that COS-7 cells expressing the C94/C99R redox-resistant eNOS had a higher dimenmonomer ratio than those expressing wildtype eNOS.
  • Treatment with H2O2, which disrupts the ZnS4 cluster inducing eNOS monomerization leads to a dose dependant decrease in eNOS dimer levels in wildtype but not C94R/C99ReNOS expressing cells (Fig. 4 A & B).
  • H2O2 which disrupts the ZnS4 cluster inducing eNOS monomerization

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne la forme endothéliale de l'oxyde nitrique synthase résistant à l'oxydoréduction et ses méthodes d'utilisation. La forme endothéliale de l'oxyde nitrique synthase résistant à l'oxydoréduction qui est décrite présente une rupture des dimères inférieure en réponse à l'oxydation par rapport à l'enzyme de type sauvage. La forme endothéliale de l'oxyde nitrique synthase résistant à l'oxydoréduction peut être utilisée pour conserver le produit oxyde nitrique dans des conditions d'oxydation, par exemple dans le traitement des maladies cardiovasculaires.
PCT/US2013/032361 2012-04-12 2013-03-15 Oxyde nitrique synthase résistant à l'oxydoréduction Ceased WO2013154771A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261623335P 2012-04-12 2012-04-12
US61/623,335 2012-04-12

Publications (1)

Publication Number Publication Date
WO2013154771A1 true WO2013154771A1 (fr) 2013-10-17

Family

ID=48182993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/032361 Ceased WO2013154771A1 (fr) 2012-04-12 2013-03-15 Oxyde nitrique synthase résistant à l'oxydoréduction

Country Status (1)

Country Link
WO (1) WO2013154771A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0045665A1 (fr) 1980-08-06 1982-02-10 Aktiebolaget Hässle Inhibiteurs d'enzymes
WO2004016764A2 (fr) * 2002-08-16 2004-02-26 Schering Aktiengesellschaft Mutants d'enos utiles pour la therapie genique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0045665A1 (fr) 1980-08-06 1982-02-10 Aktiebolaget Hässle Inhibiteurs d'enzymes
WO2004016764A2 (fr) * 2002-08-16 2004-02-26 Schering Aktiengesellschaft Mutants d'enos utiles pour la therapie genique

Non-Patent Citations (67)

* Cited by examiner, † Cited by third party
Title
"Hematopoietic Stem Cell Transplantation", 2000, MARCEL DEKKER
"Stem Cell Biology", 2001, COLD SPRING HARBOR LABORATORY PRESS
ALMQUIST ET AL., J. MED. CHEM., vol. 23, 1980, pages 1392 - 1398
BANERJI, J. L. ET AL., CELL, vol. 33, 1983, pages 729
BARKA ET AL., HISTOCHEM. CYTOCHEM., vol. 48, no. 11, 2000, pages 1453 - 60
BOHMER R M, FETAL DIAGN THER, vol. 17, 2002, pages 83
CA, vol. 97, 1982, pages 39405
CAI ET AL., CARDIOVASC RES, vol. 65, 2005, pages 823 - 31
CAI ET AL., DIABETOLOGIA, vol. 48, 2005, pages 1933 - 40
CHEN ET AL., BIOCHEMISTRY, vol. 49, 2010, pages 3129 - 37
DEROSSI ET AL., JBIOL CHEM., vol. 269, no. 14, 1994, pages 10444 - 50
ERWIN ET AL., JBIOL CHEM, vol. 280, 2005, pages 19888 - 94
ESCOBALES ET AL., CURR VASC PHARMACOL, vol. 3, 2005, pages 231 - 46
FIERS ET AL., NATURE, vol. 273, 1978, pages 113
FONSECA ET AL., DNA CELL BIOL, vol. 29, 2010, pages 149 - 60
FONSECA FABIO V ET AL: "Mass Spectroscopy and Molecular Modeling Predict Endothelial Nitric Oxide Synthase Dimer Collapse by Hydrogen Peroxide Through Zinc Tetrathiolate Metal-Binding Site Disruption", DNA AND CELL BIOLOGY, vol. 29, no. 3, March 2010 (2010-03-01), pages 149 - 160, XP002700099, ISSN: 1044-5498 *
FRANKEL; PABO, CELL, vol. 55, no. 6, 1988, pages 1189 - 93
FRESHNEY: "Culture of Animal Cells-A Manual of Basic Technique", 1994, WILEY-LISS
GREENWAY, P. J. ET AL., GENE, vol. 18, 1982, pages 355 - 360
HANN J., CHEM. SOC PERKIN TRANS. I, 1982, pages 307 - 314
HEMMENS ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, 2000, pages 35786 - 35791
HO ET AL., CANCER RES., vol. 61, no. 2, 2001, pages 474 - 7
HOLLADAY ET AL., TETRAHEDRON. LETT, vol. 24, 1983, pages 4401 - 4404
HRUBY, LIFE SCI, vol. 31, 1982, pages 189 - 199
HUDSON, D. ET AL., INT J PEPT PROT RES, vol. 14, 1979, pages 177 - 185
JAEGER ET AL., METHODS ENZYMOL., vol. 183, 1989, pages 281 - 306
JAEGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 7706 - 7710
JENNINGS-WHITE ET AL., TETRAHEDRON LETT, vol. 23, 1982, pages 2533
KABOURIDIS, P., TRENDS IN BIOTECHNOLOGY, 2003, pages 498 - 503
KNOWLES, J ET AL., J CLIN INVEST, vol. 105, 2000, pages 451 - 8
LAIMINS, L. ET AL., PROC. NATL. ACAD. SCI., vol. 78, 1981, pages 993
LI ET AL., JBIOL CHEM, vol. 274, 1999, pages 21276 - 84
LU ET AL., BIOCHIM BIOPHYSACTA, vol. 1525, 2001, pages 89 - 96
LUSKY, M. L. ET AL., MOL. CELL. BIO., vol. 3, 1983, pages 1108
MIRAGLIA, S. ET AL., BLOOD, vol. 90, 1997, pages 5013
MORLEY, TRENDS PHARM SCI, 1980, pages 463 - 468
MRABET ET AL., BIOCHEMISTRY, vol. 31, 1992, pages 2239 - 53
NASSEM, K., MOL ASPECTS MED., vol. 26, no. 1-2, 2005, pages 33 - 65
NEEDLEMAN; WUNSCH, J. MOL BIOL., vol. 48, 1970, pages 443
OSBORNE, T. F. ET AL., MOL. CELL BIO., vol. 4, 1984, pages 1293
PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 2444
PROCKOP D J, CYTOTHERAPY, vol. 3, 2001, pages 393
R. RAFIKOV ET AL: "eNOS activation and NO function: Structural motifs responsible for the posttranslational control of endothelial nitric oxide synthase activity", JOURNAL OF ENDOCRINOLOGY, vol. 210, no. 3, 1 September 2011 (2011-09-01), pages 271 - 284, XP055069514, ISSN: 0022-0795, DOI: 10.1530/JOE-11-0083 *
RAFIKOV ET AL., J. ENDOCRINOL., vol. 210, 2011, pages 271 - 84
RAFIKOV R ET AL: "Basic Amino Acid Residues Within (aa105-125) eNOS Region are Responsible for the ''Flexible Arm'' Movement and the Inhibition of ZnS4 Mutants", FREE RADICAL BIOLOGY AND MEDICINE, ELSEVIER SCIENCE, US, vol. 49, 1 January 2010 (2010-01-01), pages S101, XP027435516, ISSN: 0891-5849, [retrieved on 20100101], DOI: 10.1016/J.FREERADBIOMED.2010.10.265 *
RAMAN ET AL., CELL, vol. 95, 1998, pages 939 - 50
RAMAN ET AL., CELL, vol. 95, 1998, pages 939 - 950
RAVI ET AL., PNAS, vol. 101, 2004, pages 2619 - 2624
RAVI ET AL., PROC NATL ACAD SCI US A, vol. 101, 2004, pages 2619 - 24
RAVI ET AL., PROC NATL ACAD SCI USA, vol. 101, 2004, pages 2619 - 24
ROACH M L, METHODS MEI BIOL, vol. 185, 2002, pages 1
ROWLEY S D ET AL., BONE MARROW TRANSPLANT, vol. 21, 1998, pages 1253
SIMMONS, P. J., BLOOD, vol. 78, 1991, pages 55
SMITH A G, ANNU REV CELL DEV BIOL, vol. 17, 2001, pages 435
SMITH; WATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482
SPATOLA ET AL., LIFE SCI, vol. 38, 1986, pages 1243 - 1249
SPATOLA, A. F.: "Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins", 1983, MARCEL DEKKER, pages: 267
SPATOLA, A. F.: "Peptide Backbone Modifications", VEGA DATA, vol. 1, no. 3, March 1983 (1983-03-01)
TROUNSON A O, REPROD FERTIL DEV, vol. 13, 2001, pages 523
TUMMALA ET AL., DNA AND CELL BIOL., vol. 27, 2008, pages 25 - 33
TUMMALA ET AL., DNA CELL BIOL, vol. 27, 2008, pages 25 - 33
UCHIDA, N. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 14720
WADIA; STAN, NAT. MED., vol. 10, no. 3, 2004, pages 310 - 5
WENDER ET AL., PROC NATL ACAD SCI USA., vol. 97, no. 24, 2000, pages 13003 - 8
ZOU ET AL., J CLIN INVEST, vol. 109, 2002, pages 817 - 26
ZOU ET AL., J. OF CLINICAL INVESTIGATION, vol. 109, 2002, pages 817 - 826
ZUKER, M., SCIENCE, vol. 244, 1989, pages 48 - 52

Similar Documents

Publication Publication Date Title
US20200299654A1 (en) Cdkl5 expression variants and cdkl5 fusion proteins
WO2021087282A1 (fr) Protéines cdkl5 recombinées, thérapie génique et procédés de production
Marcus et al. Replacement of the C6ORF66 assembly factor (NDUFAF4) restores complex I activity in patient cells
CN107530407A (zh) 丙酰辅酶a羧化酶组合物及其用途
US10898550B2 (en) Compositions and methods of treating root avulsion injury
CA2903933C (fr) Methodes et compositions de conditionnement d'acides nucleiques dans les exosomes microgliaux destines a l'expression ciblee de polypeptides dans les cellules neuronales
US8663630B2 (en) Promotion of peroxisomal catalase function in cells
CN108699511B (zh) 包含过氧蛋白的无血清培养基添加剂组合物及其用途
CN103189503B (zh) 表达人胆碱乙酰转移酶的人神经干细胞及其用途
WO2013154771A1 (fr) Oxyde nitrique synthase résistant à l'oxydoréduction
CN105051061B (zh) 用于扩增干细胞的组合物和方法
KR20200039621A (ko) 미엘린 장애의 치료를 위한 조성물 및 방법
JP3965448B2 (ja) 細胞内特定部位へ物質を導入するための化合物
US20190314421A1 (en) Nucleic acid constructs including a txnip promoter for the treatment of disease
JP2006515168A5 (fr)
RU2521225C2 (ru) Способ стимулирования регенерации спинного мозга с помощью генетически модифицированных клеток крови пуповины человека
WO2011152662A9 (fr) Polypeptide de fusion ptd-uqcrb, et composition pharmaceutique destinée à prévenir et à traiter des maladies ischémiques le contenant
EP2140000A1 (fr) Procede d'amelioration de la migration de cellules neurales precurseurs
KR20140030934A (ko) 퍼옥시레독신 2 융합단백질을 함유하는 뇌 허혈손상 예방 및 치료용 약학 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13718426

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13718426

Country of ref document: EP

Kind code of ref document: A1